Summit Therapeutics registers Phase 2/3 HARMONi-GU1 trial in urothelial carcinomaSep 11Trial updateivonescimabSummit Therapeutics
Generate Biomedicines reports Q2 2026 results, advances asthma and oncology pipelineAug 6Quarterly updateGenerate Biomedicines
Summit Therapeutics starts Phase II/III bladder cancer trial for ivonescimabAug 5Clinical readoutivonescimabSummit Therapeutics
Merck posts Q2 loss on Terns charge, raises full-year sales outlookAug 4Quarterly updateMerck & Co., Inc.
Innate Pharma completes enrollment in Phase 1 study of Nectin-4 ADC IPH4502Jul 21Clinical readoutInnate PharmaIPH4502
Sign inSign in